Literature DB >> 22977398

Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes.

.   

Abstract

Entities:  

Year:  2010        PMID： 22977398      PMCID： PMC3411141     

Source DB:  PubMed          Journal:  CADTH Technol Overv        ISSN： 1203-9012


× No keyword cloud information.
  48 in total

1.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Authors:  H Yki-Järvinen; A Dressler; M Ziemen
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

2.  Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

Authors:  R E Ratner; I B Hirsch; J L Neifing; S K Garg; T E Mecca; C A Wilson
Journal:  Diabetes Care       Date:  2000-05       Impact factor: 19.112

3.  Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

Authors:  Curtis Triplitt; Leonard Glass; Yoshiniro Miyazaki; Estela Wajcberg; Amalia Gastaldelli; Elena De Filippis; Eugenio Cersosimo; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

4.  Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

Authors:  K Hermansen; S Madsbad; H Perrild; A Kristensen; M Axelsen
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

5.  Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

Authors:  Freddy G Eliaschewitz; Cesar Calvo; Humberto Valbuena; Maximino Ruiz; Pablo Aschner; Jaime Villena; Luis A Ramirez; Jorge Jimenez
Journal:  Arch Med Res       Date:  2006-05       Impact factor: 2.235

6.  Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.

Authors:  Athena Philis-Tsimikas; Guillaume Charpentier; Per Clauson; Gabriela Martinez Ravn; Victor Lawrence Roberts; Birger Thorsteinsson
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

7.  A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.

Authors:  P D Home; R Rosskamp; J Forjanic-Klapproth; A Dressler
Journal:  Diabetes Metab Res Rev       Date:  2005 Nov-Dec       Impact factor: 4.876

8.  Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.

Authors:  K Kølendorf; G P Ross; I Pavlic-Renar; G Perriello; A Philotheou; J Jendle; M-A Gall; S R Heller
Journal:  Diabet Med       Date:  2006-07       Impact factor: 4.359

9.  Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

Authors:  Philip Home; Paul Bartley; David Russell-Jones; Hélène Hanaire-Broutin; Jan-Evert Heeg; Pascale Abrams; Mona Landin-Olsson; Birgitte Hylleberg; Hanne Lang; Eberhard Draeger
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

10.  Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

Authors:  David Russell-Jones; Richard Simpson; Birgitte Hylleberg; Eberhard Draeger; Jan Bolinder
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393
View more
  2 in total

1.  Hypoglycemia in type 2 diabetes: It is common, so what strategies can minimize the risk?

Authors:  Marlys LeBras; Tessa Laubscher
Journal:  Can Fam Physician       Date:  2021-01       Impact factor: 3.275

2.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.

Authors:  Sumeet R Singh; Fida Ahmad; Avtar Lal; Changhua Yu; Zemin Bai; Heather Bennett
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.